|27 June 2016 - 08 July 2016||Surveillance consultation|
|21 June 2016||Stakeholder list updated|
|19 May 2009||The remit was received from the Department of Health and the Welsh Assembly Government in March 2009 as part of the Institutes' 21st wave work programme.|
|4 June 2010||
The scope defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table. The Guideline Development Group (GDG) oversees the development process.
The NCCs may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4weeks to respond. The NCC will approach all registered stakeholders for this evidence. The NCC may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the NCCs will accept relevant confidential data for consideration by the GDG.
Development of the clinical guideline is under way and is being led by the National Collaborating Centre. The Guideline Development Group meets regularly to oversee and assist the identification, review and synthesis of the evidence, the incorporation of expert consensus opinion and the translation of the evidence into recommendations for practice and audit criteria. Two versions of the guideline are under preparation: a full guideline and a NICE short-form guideline. Please see timescales above for dates of consultation with stakeholders.